AstraZeneca Oncology PSP for Calquence® (acalabrutinib) in Previously Untreated Mantle Cell Lymphoma (ECHO)
Dear Healthcare Provider,
This letter is to inform you that as of June 27, 2025 the AstraZeneca Oncology Patient Support Program (PSP) for CALQUENCE® (acalabrutinib) is opening for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL) in combination with bendamustine and rituximab.
The PSP for CALQUENCE in combination with bendamustine and rituximab offers:
- Reimbursement navigation support
- Co-payment towards the cost of CALQUENCE® for eligible patients, up to 40% for those with private insurance or paying out of pocket
- A free drug program offering full coverage of CALQUENCE® for eligible patients without private insurance, as described below
- Access to educational resources
Eligible patients without private insurance coverage of CALQUENCE® will have access to free drug through the PSP in line with the following criteria:
- Patients who meet the Health Canada approved indication: CALQUENCE is indicated in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplant.
- Patients with ECOG scores 0–2
- Patients who have not received prior systemic anticancer therapies for MCL
- Patients who are ineligible for Autologous Stem Cell Transplant (ASCT)
This program is subject to change at any time. In the event that changes are made to the program, prescribing physicians with patients already enrolled in the program will be notified in advance. Any eligible patients already in the program will continue to receive uninterrupted access to CALQUENCE for as long as they require treatment (according to the approved indication) or until public listings (whichever comes first).
To enroll a new patient in the PSP, please fax a completed enrolment form to 1-877-280-6221 or email it to the AstraZeneca Oncology Patient Support Program at enrollment@AZoncologypsp.ca.
Should you have any questions about the PSP program, please do not hesitate to contact us at 1-877-280-6208 (Monday to Friday, from 8:00 AM – 8:00 PM EST). If you have any questions about CALQUENCE, please contact your local AstraZeneca Canada representative.
Regards,
Your Patient Care Coordinator
AstraZeneca Oncology Patient Support Program
Attachments:
Product Monograph - CALQUENCE® (acalabrutinib) tablets - English